scholarly journals Sunitinib Plus Androgen Deprivation and Radiation Therapy for Patients With Localized High-Risk Prostate Cancer: Results From a Multi-institutional Phase 1 Study

2013 ◽  
Vol 86 (3) ◽  
pp. 540-545 ◽  
Author(s):  
Paul G. Corn ◽  
Danny Y. Song ◽  
Elisabeth Heath ◽  
Jordan Maier ◽  
Raymond Meyn ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
High Risk ◽  
Phase 1 ◽  
Androgen Deprivation ◽  
Phase 1 Study ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

Causes of Mortality After Dose-Escalated Radiation Therapy and Androgen Deprivation for High-Risk Prostate Cancer

2013 ◽  
Vol 87 (1) ◽  
pp. 94-99 ◽  
Author(s):  
Rahul D. Tendulkar ◽  
Grant K. Hunter ◽  
Chandana A. Reddy ◽  
Kevin L. Stephans ◽  
Jay P. Ciezki ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
High Risk ◽  
Androgen Deprivation ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer ◽  
Causes Of Mortality

scholarly journals Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing Controversies

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Aditya Juloori ◽  
Chirag Shah ◽  
Kevin Stephans ◽  
Andrew Vassil ◽  
Rahul Tendulkar
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
High Risk ◽  
Androgen Deprivation Therapy ◽  
Randomized Trials ◽  
Androgen Deprivation ◽  
External Beam Radiation ◽  
Beam Radiation ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

High-risk prostate cancer is an aggressive form of the disease with an increased risk of distant metastasis and subsequent mortality. Multiple randomized trials have established that the combination of radiation therapy and long-term androgen deprivation therapy improves overall survival compared to either treatment alone. Standard of care for men with high-risk prostate cancer in the modern setting is dose-escalated radiotherapy along with 2-3 years of androgen deprivation therapy (ADT). There are research efforts directed towards assessing the efficacy of shorter ADT duration. Current research has been focused on assessing hypofractionated and stereotactic body radiation therapy (SBRT) techniques. Ongoing randomized trials will help assess the utility of pelvic lymph node irradiation. Research is also focused on multimodality therapy with addition of a brachytherapy boost to external beam radiation to help improve outcomes in men with high-risk prostate cancer.

Phase 1 Trial of Neoadjuvant Radiation Therapy Before Prostatectomy for High-Risk Prostate Cancer

2013 ◽  
Vol 87 (1) ◽  
pp. 88-93 ◽  
Author(s):  
Bridget F. Koontz ◽  
Brian P. Quaranta ◽  
John A. Pura ◽  
W.R. Lee ◽  
Zeljko Vujaskovic ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
High Risk ◽  
Phase 1 ◽  
Phase 1 Trial ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document